{
    "root": "77bb27a8-b20e-44eb-b96c-ff1a364a24d1",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Letrozole",
    "value": "20250131",
    "ingredients": [
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A",
            "code": "H8AV0SQX4D",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "HYPROMELLOSE 2208 (100 MPA.S)",
            "code": "B1QE5P712K",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LETROZOLE",
            "code": "7LKK855W8I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6413"
        }
    ],
    "indications": {
        "text": "letrozole tablets , usp aromatase inhibitor indicated : adjuvant treatment postmenopausal women hormone receptor positive early breast cancer ( 1.1 ) extended adjuvant treatment postmenopausal women early breast cancer received prior standard adjuvant tamoxifen therapy ( 1.2 ) first second-line treatment postmenopausal women hormone receptor positive unknown advanced breast cancer ( 1.3 )",
        "doid_entities": [
            {
                "text": "breast cancer (DOID:1612)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1612"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "letrozole tablets taken orally without regard meals ( 2 ) : recommended dose : 2.5 mg daily ( 2.1 ) patients cirrhosis severe hepatic impairment : 2.5 mg every day ( 2.5 , 5.3 )",
        "doid_entities": [
            {
                "text": "cirrhosis (DOID:5082)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5082"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "packaged hdpe bottles safety screw cap . letrozole tablets , usp 2.5 mg bottles 30 tablets : ndc 71335-2396-1 bottles 10 tablets : ndc 71335-2396-2 bottles 90 tablets : ndc 71335-2396-3 bottles 40 tablets : ndc 71335-2396-4 store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "\u25cf pregnancy : letrozole cause fetal harm [ ( 8.1 ) ] . \u25cf known hypersensitivity active substance , excipients [ ( 6 ) ] .",
    "indications_original": "Letrozole Tablets, USP are aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 )",
    "contraindications_original": "Letrozole tablets are taken orally without regard to meals ( 2 ): Recommended dose: 2.5 mg once daily ( 2.1 ) Patients with cirrhosis or severe hepatic impairment: 2.5 mg every other day ( 2.5 , 5.3 )",
    "warningsAndPrecautions_original": "Packaged in HDPE bottles with a safety screw cap.\n                  Letrozole Tablets, USP 2.5 mg\n                  \n                     Bottles of 30 tablets: NDC 71335-2396-1\n                     Bottles of 10 tablets: NDC 71335-2396-2\n                     Bottles of 90 tablets: NDC 71335-2396-3\n                     Bottles of 40 tablets: NDC 71335-2396-4\n                  \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature].\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "\u25cf Pregnancy: Letrozole can cause fetal harm \n        \n \n   [see \n         \n  \n    Use in\n                        \n                        \n                            Specific Populations (8.1)]\n        \n \n   . \n       \n\n  \n                  \n                  \n                     \u25cf Known hypersensitivity to the active substance, or to any of the excipients \n        \n \n   [see \n         \n  \n    Adverse Reactions (6)]\n        \n \n   .",
    "drug": [
        {
            "name": "Letrozole",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6413"
        }
    ]
}